# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Locke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN001-SYN
- Date: 2026-03-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Prudence Hartwell-Osei, MD
- Calendar frame: modern shifted

## What we are working on

- He has coughed for twenty years, and the city air leaves him unable to breathe; he wants to be able to do his work there **S**
- He wonders whether this is the consumption that his father and brother had **S**
- He asks whether the fire in his study is part of the problem **S**

## Your goals

- Cause of the cough and breathlessness established by the second visit. Target: 2026-03-26. Recorded outcome: Asthma with persistent airflow limitation confirmed by spirometry, FeNO, eosinophils, DLCO, and CT; tuberculosis, alpha-1 antitrypsin deficiency, and heart failure excluded. **S**
- Asthma well controlled (Asthma Control Test 20 or more) with no flare needing oral corticosteroids. Target: 2027-03-31. Recorded outcome: ACT 21 at the last visit; one yellow-zone flare with a cold, managed by the action plan without oral corticosteroids. **S**
- No indoor solid-fuel smoke and less outdoor pollution exposure. Target: 2027-03-31. Recorded outcome: Open fires out of use since intake; HEPA air cleaner in his study and bedroom; air quality alerts followed. **S**
- Six-minute walk distance improved by at least 30 m after pulmonary rehabilitation. Target: 2026-06-18. Recorded outcome: 430 m before and 505 m after an eight-week program. **S**

## What we agreed to do

- Diagnostic workup: spirometry before and after bronchodilator, FeNO, DLCO, blood count with eosinophils, total IgE, alpha-1 antitrypsin, NT-proBNP, interferon-gamma release assay, chest X-ray, and CT of the chest if airflow limitation persists after bronchodilator; albuterol withheld for 6 hours before testing. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023) **S**
- Exposure reduction from today: no open coal or wood fires in his rooms (electric or heat-pump heating instead); a portable HEPA air cleaner sized for his study and bedroom; daily check of the air quality index, with city trips and outdoor exertion avoided on alert days; a well-fitted N95 respirator on unavoidable high-pollution days; quieter routes away from main roads. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021); Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020); AQI Basics (2026); Air Cleaners and Air Filters in the Home (2026) **S**
- Pulmonology consultation on the diagnosis (asthma, COPD, or both), the need for CT, treatment, and pulmonary rehabilitation. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025) **S**
- Shared decision on treatment: budesonide-formoterol 160/4.5 mcg as maintenance and reliever, two inhalations twice daily plus one as needed, no more than 12 a day; albuterol stopped; inhaler technique taught and checked at every visit; a written asthma action plan. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
- Pulmonary rehabilitation: an eight-week, twice-weekly program of supervised exercise training and education, with a six-minute walk test before and after. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023) **S**
- Vaccinations: pneumococcal conjugate vaccine PCV20 at the diagnosis visit; influenza, COVID-19, and RSV vaccines in the autumn; recombinant zoster vaccine. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Adult Immunization Schedule by Age (2026) **S**
- Monitoring: Asthma Control Test, inhaler technique, adherence, reliever use, and exposures at every visit; spirometry and FeNO 3 months after starting treatment, then every 1 to 2 years; home peak flow diary. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
- Add-on tiotropium 2.5 mcg soft-mist inhaler, two inhalations once daily, for persistent symptoms and airflow limitation on medium-dose budesonide-formoterol; written action plan updated with peak-flow zones from his personal best of 440 L/min. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
- After any flare: a review within one week, booked by the clinic when he calls or is seen for the flare. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**

## Follow-up

- 2026-03-12: Primary care visit for a lifelong cough with wheeze and breathlessness, worse in city air and by open fires, in a never-smoker **S**
- 2026-03-26: Two-week review of lung function and blood tests, diagnosis, start of treatment, and pulmonology consultation **S**
- 2026-06-18: Twelve-week asthma review with repeat spirometry after pulmonary rehabilitation **S**
- 2026-09-17: Preventive health visit at 60 **S**
- 2026-10-22: Asthma review two weeks after a cold with a yellow-zone flare **S**

This teaching document does not replace care from a qualified clinician.
